OPRX241220P15000
- 0.00
- 0.000.00%
OptimizeRx Newsroom
Stifel Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $8
Roth MKM Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $16
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Ontrak (OTRK) and Ayr Wellness (OtherAYRWF)
OptimizeRx Is Maintained at Market Outperform by JMP Securities
OptimizeRx Analyst Ratings
RBC Capital Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $7
Barclays Sticks to Their Hold Rating for OptimizeRx (OPRX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: PTC Therapeutics (PTCT), Medtronic (MDT) and OptimizeRx (OPRX)
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $8
OptimizeRx: Buy Rating Affirmed Amid Financial Efficiency and Business Model Shift
Lake Street Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $15
Lake Street Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $15
Lake Street Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $15
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $16
Lake Street Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $15
OptimizeRx Analyst Ratings
RBC Capital Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $14
OptimizeRx Price Target Cut to $11.00/Share From $15.00 by Barclays
OptimizeRx Analyst Ratings
Barclays Sticks to Its Hold Rating for OptimizeRx (OPRX)